Ana Gomez-Palazzo practices in the intellectual property transactions and life sciences groups at Ropes & Gray, advising clients on a wide range of strategic transactions, including license agreements, complex collaborations, mergers and acquisitions, supply and distribution agreements, and other commercial transactions where intellectual property is a key consideration.


  • Advised Ionis Pharmaceuticals in a $3.5 billion collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis’ antisense medicine for the treatment of transthyretin amyloidosis protein.  
  • Represented Pfizer Inc. in a $1.24 billion dollar ex-U.S. strategic collaboration agreement with Biohaven Pharmaceutical Company to commercialize rimegepant, a therapy approved in the U.S. as Nurtec ODT for the acute treatment of migraine attacks and the preventative treatment of episodic migraines. 
  • Represented Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, in a $1 billion dollar worldwide co-development and co-commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for four novel neurology drugs, two of which are in Phase 3 development.  
  • Advised Belgian biopharmaceutical company iTeos Therapeutics in a $2 billion collaboration with global health care leader GSK to co-develop and co-commercialize an anti-TIGIT monoclonal antibody as a potential treatment for cancer patients.
  • Represented a global biopharmaceutical company in its collaboration, option and license agreement with a clinical stage biotechnology company to research and develop a vaccine-based immunotherapy for human immunodeficiency virus (HIV) infection.
  • Advised Gilead Sciences, Inc. on intellectual property/licensing matters related to its $1.55 billion exclusive option to acquire Tizona Therapeutics, Inc.
  • Represented Ginkgo Bioworks in a number of transactions, including a strategic partnership with Aldevron to optimize production of vaccinia capping enzymes (VCE). 
  • Advised Bain Capital in its $125 million non-dilutive financing with Cerevel Therapeutics to fund the Phase 3 development program for tavapadon in Parkinson's disease, also known as the TEMPO trials.

Areas of Practice